Note: This article is for educational publishing purposes only and does not replace medical advice, diagnosis, or treatment from a licensed healthcare professional. Xofigo is a prescription radiopharmaceutical that must be handled and administered by trained, authorized medical teams.
Xofigo, known by its generic name radium Ra 223 dichloride, is not your average “take two tablets and call me in the morning” medication. It is a radioactive cancer treatment used in a very specific group of patients: men with castration-resistant prostate cancer that has spread to the bones, is causing symptoms, and has not spread to organs such as the liver or lungs. In simpler language, Xofigo is designed for prostate cancer that keeps growing even when testosterone is kept very low, and it is especially aimed at painful or troublesome bone metastases.
That sounds intense because, frankly, it is. But the clever part is how Xofigo behaves once it enters the body. Radium-223 mimics calcium, so it naturally travels toward areas of active bone turnover. Bone metastases are like construction zones with too many warning cones and not enough supervisors; Xofigo heads toward those busy areas and releases short-range alpha radiation that damages nearby cancer cells while limiting exposure to more distant normal tissues.
What Is Xofigo?
Xofigo is an alpha particle-emitting radiotherapeutic drug. It is supplied as a clear, colorless, sterile solution for intravenous injection. Patients do not store it at home, do not inject it themselves, and definitely do not keep it in the medicine cabinet next to the cough drops. It is handled under radiation-safety rules in authorized medical settings.
The treatment is used as part of advanced prostate cancer care, often alongside other supportive strategies for pain control, bone health, and symptom management. It is not used for every prostate cancer case, and it is not meant for localized prostate cancer confined to the prostate gland. Its sweet spotmedically speaking, not dessert-menu speakingis metastatic castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastatic disease.
Xofigo Uses: Who Is It For?
Primary FDA-approved use
Xofigo is approved for patients with prostate cancer that no longer responds to medical or surgical treatment that lowers testosterone. The cancer must have spread to the bones and be causing symptoms, but there should be no known spread to internal organs. This distinction matters because Xofigo targets bone metastases; it is not designed to treat soft-tissue or organ metastases in the same way chemotherapy, hormonal therapy, immunotherapy, or other systemic treatments might.
Why bone metastases matter
When prostate cancer spreads to bone, it can cause pain, fractures, spinal cord compression, and reduced mobility. Xofigo was studied not only for survival but also for delaying symptomatic skeletal events, such as the need for external beam radiation to relieve bone symptoms, new painful bone fractures, spinal cord compression, or orthopedic surgery related to tumors.
How Xofigo Works
Radium-223 behaves like calcium and binds with bone mineral called hydroxyapatite, especially in areas where bone turnover is high. Once there, it emits alpha particles. Alpha particles travel only a short distanceless than 100 micrometers, or fewer than about 10 cell diametersso the treatment can concentrate its effect near metastatic bone lesions while limiting damage to surrounding tissue.
The alpha radiation causes double-strand DNA breaks in nearby cells, including tumor cells, osteoblasts, and osteoclasts. That DNA damage is part of the anti-tumor effect. Think of it as a tiny demolition crew sent to the wrong construction site on purpose: very local, very focused, and not something you want wandering around unsupervised.
Xofigo Dosing and Administration
Standard dosing schedule
The recommended Xofigo dose is 55 kBq per kilogram of body weight, given by slow intravenous injection once every 4 weeks for a total of 6 injections. Safety and effectiveness beyond 6 injections have not been established.
How the injection is given
Xofigo is administered by slow IV injection over about 1 minute. The IV line is flushed with isotonic saline before and after the dose. Because radium-223 decays over time, the treatment team calculates the dose using body weight, radioactivity concentration, and a decay correction factor. That is why this is not a “close enough” medication; precision is part of the prescription.
Before each dose
Blood counts must be checked before treatment starts and before every dose. Before the first Xofigo injection, the absolute neutrophil count should be at least 1.5 x 109/L, platelet count at least 100 x 109/L, and hemoglobin at least 10 g/dL. Before later doses, the absolute neutrophil count should be at least 1 x 109/L and platelets at least 50 x 109/L.
Xofigo Side Effects
The most common side effects reported with Xofigo include nausea, diarrhea, vomiting, and swelling of the hands, feet, or legs, also called peripheral edema. In the randomized clinical trial, nausea occurred in 36% of Xofigo-treated patients, diarrhea in 25%, vomiting in 19%, and peripheral edema in 13%.
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Swelling in the hands, feet, or legs
- Fatigue related to anemia or advanced cancer
- Injection-site redness, pain, or swelling in some patients
Blood-related side effects
Xofigo can suppress bone marrow, which may lower red blood cells, white blood cells, and platelets. Laboratory abnormalities reported in clinical trials included anemia, lymphocytopenia, leukopenia, thrombocytopenia, and neutropenia. These issues can raise the risk of tiredness, shortness of breath, infection, bruising, and bleeding.
Serious symptoms to report quickly
Patients should contact their healthcare team right away for unusual bleeding or bruising, fever, chills, sore throat, signs of infection, severe diarrhea, dehydration, reduced urination, shortness of breath, or extreme fatigue. These symptoms do not automatically mean something catastrophic is happening, but they do mean the oncology team should be looped in fastpreferably before “I’ll just Google it” becomes the treatment plan.
Xofigo Warnings and Precautions
Bone marrow suppression
Bone marrow suppression is one of the major warnings for Xofigo. In the randomized trial, bone marrow failure or ongoing pancytopenia occurred in 2% of patients receiving Xofigo compared with none in the placebo group. Some cases were fatal. Patients with compromised bone marrow reserve need close monitoring, and Xofigo may need to be delayed, discontinued, or managed with supportive care if blood counts do not recover.
Fracture and mortality warning with abiraterone plus prednisone or prednisolone
Xofigo is not recommended in combination with abiraterone acetate plus prednisone or prednisolone. In one clinical study, patients receiving the combination had a higher incidence of fractures and deaths than patients receiving placebo with abiraterone and prednisone or prednisolone. This is one of the most important interaction-style warnings patients should know before starting treatment.
Dehydration risk
Because Xofigo can cause nausea, vomiting, and diarrhea, dehydration can become a problem. The prescribing information advises monitoring oral intake, fluid status, and urine output. Patients should report dry mouth, dizziness, dark urine, reduced urination, or inability to keep fluids down. In cancer care, hydration is not glamorous, but neither is passing out in the hallway, so it deserves attention.
Radiation safety at home
After Xofigo, there are generally no restrictions on casual contact with other people, but radiation can be present in body fluids for a period after treatment. Patients are usually told to use good bathroom hygiene, flush the toilet several times, wash hands thoroughly, and wash clothing soiled with urine or feces separately. Caregivers may be advised to wear gloves when handling body fluids.
Pregnancy, fertility, and contraception
Xofigo is not approved for use in females and can cause fetal harm based on its mechanism of action. Male patients should use condoms, and female partners who can become pregnant should use effective contraception during treatment and for 6 months after the final dose. Xofigo may also impair male fertility.
Xofigo Interactions
No formal clinical drug interaction studies have been performed with Xofigo. However, the major practical warning is avoiding use with abiraterone acetate plus prednisone or prednisolone because of increased fracture and mortality findings. Patients should also tell their doctor about chemotherapy, other radiopharmaceuticals, radiation therapy, bone-targeting agents, prescription medicines, over-the-counter products, vitamins, and supplements.
Subgroup analyses in the randomized trial suggested that concurrent bisphosphonates or calcium channel blockers did not affect Xofigo safety and efficacy. That does not mean every medication is automatically safe to combine. It means the oncology team should review the whole medication list, because cancer regimens can get complicated enough to deserve their own spreadsheet and possibly a tiny air-traffic-control tower.
What Does Xofigo Look Like? Pictures and Packaging
Patients searching for “Xofigo pictures” usually want to know what the medication or packaging looks like. Xofigo is supplied as a clear, colorless, sterile solution in a single-dose vial. Each vial contains 6 mL of solution at a reference radioactivity concentration of 1,100 kBq/mL, with total radioactivity of 6,600 kBq per vial at the reference date. The vial is labeled for intravenous administration and is handled in radiation-shielded clinical settings.
In real life, most patients will not spend much time admiring the vial. Xofigo is not a medicine you pose for a bathroom-counter photo shoot. It arrives, is checked, measured, administered, and disposed of according to radiopharmaceutical safety rules.
Clinical Evidence: Does Xofigo Help?
The pivotal ALSYMPCA trial studied men with metastatic castration-resistant prostate cancer and symptomatic bone metastases. Patients received radium-223 or placebo plus best standard of care. In updated results, median overall survival was 14.9 months with radium-223 compared with 11.3 months with placebo. The treatment also delayed time to first symptomatic skeletal event.
Those numbers do not mean every individual patient will live exactly that long or benefit in the same way. Cancer biology is not a vending machine: insert treatment, receive identical outcome. But the study showed a meaningful survival benefit in the specific population studied, which is why Xofigo became an important option in advanced prostate cancer care.
Patient-Experience Perspective: What Treatment May Feel Like
For many patients, the first surprise about Xofigo is how quick the appointment can feel compared with the emotional weight of the word “radioactive.” The injection itself is usually brief, but the visit may include check-in, lab review, safety verification, dose preparation, and post-treatment instructions. The medical choreography can feel like a very serious backstage production: everyone has a role, nobody wants improvisation, and the star of the show is a tiny vial that absolutely requires respect.
Before treatment begins, patients often go through a review of scans, symptoms, blood counts, prior treatments, and current medications. This is where communication matters. A patient should tell the oncology team about bone pain, recent falls, dental issues, fractures, fatigue, infections, bleeding, bowel problems, and all medications. Even supplements count. The “it’s natural, so it doesn’t matter” theory has caused more medical confusion than a printer error message.
During the treatment course, the most noticeable day-to-day issues may be gastrointestinal symptoms, fatigue, swelling, or the emotional rhythm of waiting for the next blood test. Some patients feel relatively normal after an injection; others may need more rest or hydration. Because diarrhea, nausea, and vomiting can lead to dehydration, it helps to plan simple meals, keep fluids nearby, and ask the care team early about anti-nausea or anti-diarrhea strategies rather than trying to tough it out like a cowboy in a pharmaceutical commercial.
Blood-count monitoring can become one of the most important parts of the experience. Patients may not feel a low platelet count or low white blood cell count right away, which is why lab appointments are not optional decoration. If fever, unusual bruising, nosebleeds, bleeding gums, shortness of breath, or severe fatigue appears, it is time to call the healthcare team. With Xofigo, the quiet details matter.
At home, radiation-safety instructions are usually manageable but should be followed carefully. Patients may be told to sit while urinating to reduce splashing, flush the toilet more than once, wash hands well, and keep soiled laundry separate. These steps may feel awkward at first, but they are practical, temporary, and designed to protect caregivers and family members from unnecessary exposure through body fluids.
Emotionally, Xofigo treatment can bring mixed feelings. Some patients feel hopeful because the therapy targets bone metastases in a scientifically elegant way. Others feel anxious because “radioactive injection” sounds like something from a comic-book origin story, minus the fun superpowers. A helpful approach is to bring a written question list to appointments: What are my latest blood counts? Should I take a bone-strengthening medicine? What side effects should trigger an urgent call? How will we know whether treatment is helping? What comes next after six injections?
Caregivers also need support. They may help with transportation, symptom tracking, meals, hydration, laundry precautions, and appointment notes. Their job is not to become amateur oncologists; their job is to help the patient stay safe, comfortable, and connected to the medical team. The best cancer-care experiences usually involve fewer heroic guesses and more boring-but-beautiful communication.
Practical Questions to Ask Your Doctor
- Am I a good candidate for Xofigo based on my scans and symptoms?
- Do I have any visceral metastases that would affect treatment choice?
- What are my baseline hemoglobin, neutrophil, and platelet counts?
- Should I receive a bone-protective agent to reduce fracture risk?
- Which medications should I stop, avoid, or review before treatment?
- What side effects should make me call immediately?
- How will we track benefit: pain, alkaline phosphatase, scans, quality of life, or other markers?
Conclusion
Xofigo (radium Ra 223 dichloride) is a specialized radiopharmaceutical treatment for men with castration-resistant prostate cancer that has spread to the bones, is causing symptoms, and has not spread to internal organs. Its value comes from its bone-targeting behavior: radium-223 mimics calcium, travels to areas of increased bone turnover, and releases short-range alpha radiation near bone metastases.
The treatment is given as an IV injection every 4 weeks for 6 total doses, with careful blood-count monitoring before each dose. Common side effects include nausea, diarrhea, vomiting, and swelling in the extremities, while serious concerns include bone marrow suppression, dehydration, fertility risks, and increased fractures and mortality when used with abiraterone plus prednisone or prednisolone.
For the right patient, Xofigo can be an important part of advanced prostate cancer care. But it is not a casual medication, not a home remedy, and not a one-size-fits-all answer. The smartest path is a detailed discussion with an oncology team that understands prostate cancer, bone metastases, radiopharmaceutical therapy, blood-count monitoring, and the patient’s overall treatment goals.
